Beth Brinsdon
President, Trialwise, Inc.
In her more than 20 years of experience working in a variety of roles in clinical research, Beth Brinsdon has developed a valued, thorough, and nuanced understanding of investigational product development and what it takes to execute clinical trials, including the complexity of data sources and their interface with clinical databases, data monitoring, the CRO landscape, and Good Clinical Practice. Her therapeutic area expertise includes oncology, CNS, and clinical pharmacology studies.
The president and founder of Trialwise, a boutique CRO, Ms. Brinsdon regularly consults with and directs clinical research activities for small-to-midsize biotech companies and startups. Ms. Brinsdon views her work as collaborative, and has developed strong working relationships with other CROs, government agencies, as well as academic research centers, such as UT MD Anderson Cancer Center, and Memorial-Sloan Kettering Cancer Center. Ms. Brinsdon’s CRO, Trialwise, focuses on planning and execution of phase 1 and phase 2 studies for a small number of private and government clients.
Prior to founding Trialwise, Ms. Brinsdon provided operational oversight for early and late phase programs for Fortune 500 companies, including global submissions of blockbuster products. She is a frequent speaker and trainer on topics including Good Clinical Practices and optimized clinical study workflow at national conferences.
Ms. Brinsdon studied psychology and zoology at Brigham Young University and holds an MBA from the C.T. Bauer College of Business at the University of Houston.